Evaluation of the face validity of reserpine administration as an animal model of depression-Parkinson's disease association

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 26, Issue 5, 2002, Pages 879-883

  Skalisz, Luana L ^a   Beijamini, Vanessa ^a   Joca, Samia L ^a   Vital, Maria A B F ^a   Da Cunha, Claudio ^a   Andreatini, Roberto ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Animal model; Depression; Face validity; Parkinson's disease; Reserpine

Indexed keywords

RESERPINE;

ACCURACY; ANHEDONIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; FLUID INTAKE; LOCOMOTION; MALE; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PARKINSON DISEASE; SUGAR INTAKE; SYMPTOMATOLOGY;

ANIMALS; BEHAVIOR, ANIMAL; DEPRESSION; DISEASE MODELS, ANIMAL; FOOD PREFERENCES; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MOTOR ACTIVITY; PARKINSON DISEASE; RESERPINE;

EID: 0036592361     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(01)00333-5     Document Type: Article

References (29)

1. Almeida R.N., Navarro D.S., Assis T.S., Medeiros I.A., Thomas G. Antidepressant effect of an ethanolic extract of the leaves of Cissampelos sympodialis in rats and mice. J. Ethnopharmacol. 63:1998;247-252.
2. American Psychiatric Association DSM-IV - Diagnostic and Statistical Manual of Mental Disorders. fourth ed. 1994;American Psychiatric Association, Washington, DC.
3. Barbosa E.R., Limongi J.C.P., Cummings J.L. Parkinson's disease. Miguel E.C., Rauch S.L., Leckman J.F. The Psychiatric Clinics of North America Volume 20 Number 4: Neuropsychiatry of the Basal Ganglia. 1997;769-790 Saunders, Philadelphia.
4. Birkmayer W., Riederer P. Die parkinson-krankheit: biochemie, klinik, therapie, 2. AUFL. 1985;Springer, Wien.
5. Bourin M. Is it possible to predict the activity of a new antidepressant in animals with simple psychopharmacological tests? Fundam. Clin. Pharmacol. 4:1990;49-64.
6. Caley C.F., Friedman J.H. Does fluoxetine exacerbate Parkinson's disease? J. Clin. Psychiatry. 53:1992;278-282.
7. Camarini R., Andreatini R., Monteiro M.G. Prolonged treatment with carbamazepine increases the stimulatory effects of ethanol in mice. Alcohol. 12(3):1995;305-308.
8. Cantello R., Aguggia M., Gilli M., Delsedime M., Cutin I.C., Riccio A., Mutani R. Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse. J. Neurol., Neurosurg. Psychiatry. 52:1989;724-731.
9. Carlsson A. Monoamine-depleting drugs. Pharmacol. Ther. 1:1975;393-400.
10. Chan-Palay V., Asan E. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of Alzheimer type and in Parkinson's disease with and without dementia and depression. J. Comp. Neurol. 287(3):1989;373-392.
11. Colpaert F.C. Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rats. Neuropharmacology. 26:1987;1431-1440.
12. Dutra R.C., Andreazza A.P., Andreatini R., Tufik S., Vital M.A.B.F. Behavioral effects of MK-801 on reserpine-treated mice. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2002;. in press.
13. Forbes N.F., Stewart C.A., Matthews K., Reid I.C. Chronic mild stress and sucrose consumption: validity as a model of depression. Physiol. Behav. 60(6):1996;1481-1484.
14. Gerlach M., Riederer P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of disease in man. J. Neural Transm. 103:1996;987-1041.
15. Gotham A.M., Brown R.G., Marsden C.D. Depression in Parkinson's disease: a quantitative and qualitative analysis. J. Neurol., Neurosurg. Psychiatry. 49:1986;381-389.
16. 1A receptors in the forced swimming wheel test in the reserpine-treated mice. Life Sci. 52:1993;1741-1749.
17. Kaur S., Starr M.S. Antiparkinsonian action of dextramethorphan in the reserpine-treated mouse. Eur. J. Pharmacol. 280:1995;159-166.
18. Matthews K., Forbes N., Reid I.C. Sucrose consumption as a hedonic measure following chronic unpredictable mild stress. Physiol. Behav. 57(2):1995;241-248.
19. Mayeux R., Stern Y., Cote L., Williams J.B.W. Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology. 39:1984;642-646.
20. Meco G., Bonifati V., Fabrizio E., Venacore N. Worsening of Parkinsonism with fluvoxamine: two cases. Hum. Psychopharmacol. 9(6):1994;439-441.
21. Menzaghi F., Whelan K.T., Risbrough V.B., Rao T.S., Lloyd G.K. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats. J. Pharmacol. Exp. Ther. 280:1997;393-401.
22. Monleon S., D'aquila P., Parra A., Simon V.M., Brain P.F., Willner P. Attenuation of sucrose consumption in mice by chronic mild stress and its restoration by imipramine. Psychopharmacology. 117:1995;453-457.
23. Moreau J.-L., Jenck F., Martin J.R., Mortas P., Haefely W.E. Antidepressant treatment prevents chronic unpredictable mild stress-induced anhedonia as assessed by ventral tegmentum self-stimulation behavior in rats. Eur. Neuropsychopharmacol. 2:1992;43-49.
24. Papp M., Lappas S., Muscat R., Willner P. Attenuation of place preference conditioning but not place aversion conditioning by chronic mild stress. J. Psychopharmacol. 6:1992;352-356.
25. Starkstein S.E., Preziosi T.J., Bolduc P.L., Robinson R.G. Depression in Parkinson's disease. J. Nerv. Ment. Dis. 178(1):1990;27-31.
26. Weiss J.M. Does decreased sucrose intake indicate loss of preference in CMS model? Psychopharmacology. 134:1997;368-370.
27. Willner P. Validation criterion for animal models of human mental disorders: learned helplessness as a paradigm case. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 10:1986;677-690.
28. Willner P. Animal models as simulations of depression. Trends Pharmacol. Sci. 12:1991;131-136.
29. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology. 134:1997;319-329.